Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 6, 1998

View Archived Issues

M-5011, a novel NSAID, shown to inhibit vertebral bone loss in arthritic rats

SmithKline Beecham to market smoking cessation patch in China

SB acquires stake in Romanian pharmaceutical market

Inex to focus internal R&D program on three cancer drug product candidates

Aurora Biosciences completes first stage of UHTSS for Warner-Lambert

Canadian research team uncovers genetic basis of epileptic disorder

Antitumor agents with high potency and selectivity under evaluation at Shionogi

Banyu patents new series of NPY antagonists for obesity, bulimia, diabetes

Tanabe presents new antidiabetic agents

Basic research in the field of vitronectin antagonists revealed by HMR

Glycylcycline antibiotic enters clinical testing

Ono discloses compounds with high binding affinity for prostanoid EP4 receptors

Dopamine reuptake inhibitors synthesized at Pola, useful for Parkinson's disease

HMR-3647: the first ketolide to reach advanced-stage clinical testing

Preclinical profile of BI-397, a promising new glycopeptide antibiotic

MiKasome phase I data presented at ICAAC; development update

Lilly glycopeptide advances to phase II for various resistant infections

Novel acid-stable macrolides from Abbott presented at ICAAC

Abbott obtains new ketolides with improved activity against MLS-resistant strains

New lead anti-HIV compound discovered by Italian university researchers

The PAF antagonist MFH-1 shows potential as an adjunct in the therapy of AIDS

Potent, orally absorbed HIV-1 protease inhibitors selected from series of azadipeptides

New broad-spectrum anti-MRSA pyrrolidinone cephalosporin and water-soluble prodrug from Roche

La Jolla enrolls patients in phase II/III trial for lupus treatment

Osiris begins clinical trials with hMSC product in cancer patients

Lidak proposes name change to Avanir

Centocor exercises option for license to HuMAb-Mouse technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...